Cowen Philip J, Ogilvie Alan D, Gama Joubert
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
Curr Med Res Opin. 2005 Mar;21(3):345-56. doi: 10.1185/030079905X30680.
Major depressive disorders (MDD) present a significant public health problem, in terms of burden for individual sufferers, their families and society as a whole. Recently, dualacting antidepressants, which block both serotonin (5-HT) and noradrenaline (NA) reuptake, have been developed with the hope of improving depression treatment outcomes. Duloxetine is a dual reuptake inhibitor of 5-HT and NA that has recently been licensed in the USA for the treatment of MDD.
This paper summarises efficacy and tolerability data for duloxetine with particular reference to the dose recommended for clinical use -- 60 mg once daily. Papers relating to duloxetine 60 mg once daily were identified through Medline searches and the publication databases at Eli Lilly/Boehringer Ingelheim.
Randomised, placebo-controlled studies have demonstrated the efficacy of duloxetine 60 mg once daily for the treatment of depression in the short and long term. Thus, duloxetine 60 mg once daily was superior to placebo in reducing once daily was superior to placebo in reducing MDD symptoms according to the primary efficacy MDD symptoms according to the primary efficacy measure -- the 17-item Hamilton Depression Rating Scale (HAMD(17)). Significantly greater improvements in subfactors of HAMD(17) and quality of life measures were also seen. In addition, duloxetine has been shown significantly to reduce the general aches and pains that frequently accompany MDD. A recent placebo-controlled study demonstrated that duloxetine improved cognition and depression measures in depressed elderly patients. Duloxetine appears to have an acceptable tolerance. The most frequently observed adverse events with duloxetine were nausea, dry mouth and somnolence. Importantly, duloxetine did not appear to have a clinically significant effect on blood pressure.
In summary, duloxetine 60 mg once daily is effective for the treatment of core depressive symptoms, as well as general aches and pains associated with depression.
重度抑郁症(MDD)给个体患者、其家庭乃至整个社会都带来了沉重负担,是一个重大的公共卫生问题。近来,研发出了同时阻断5-羟色胺(5-HT)和去甲肾上腺素(NA)再摄取的双重作用抗抑郁药,以期改善抑郁症的治疗效果。度洛西汀是一种5-HT和NA双重再摄取抑制剂,最近已在美国获批用于治疗MDD。
本文总结度洛西汀的疗效和耐受性数据,尤其参考临床使用推荐剂量——每日一次60毫克。通过检索Medline以及礼来/勃林格殷格翰的出版物数据库,找出了与每日一次60毫克度洛西汀相关的文献。
随机、安慰剂对照研究已证明,每日一次60毫克度洛西汀在短期和长期治疗抑郁症方面均有效。因此,根据主要疗效指标——17项汉密尔顿抑郁评定量表(HAMD(17)),每日一次60毫克度洛西汀在减轻MDD症状方面优于安慰剂。在HAMD(17)的子因素和生活质量指标方面也有显著更大的改善。此外,度洛西汀已被证明能显著减轻MDD常伴有的全身疼痛。最近一项安慰剂对照研究表明,度洛西汀改善了老年抑郁症患者的认知和抑郁指标。度洛西汀的耐受性似乎尚可。度洛西汀最常观察到的不良事件是恶心、口干和嗜睡。重要的是,度洛西汀似乎对血压没有临床显著影响。
总之,每日一次60毫克度洛西汀对治疗核心抑郁症状以及与抑郁症相关的全身疼痛有效。